Tocilizumab, an IL-6 receptor antagonist which prevents IL-6 from binding to both cell-associated and soluble IL-6R, is currently the only US-FDA approved therapy for treating CAR-T cell-associated CRS [68]. Here, IL6 is linked to congenital rubella syndrome.